Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.

@article{Saven1996CladribineAM,
  title={Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.},
  author={Alan Saven and Tom C N Lee and Michael P. Kosty and L. Di Piro},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 7},
  pages={2139-44}
}
PURPOSE Since cladribine (2-chlorodeoxyadenosine [2-CdA]) and mitoxantrone both exhibit major activity against indolent lymphoid malignancies and have different mechanisms of action, we performed a dose-escalation study of 2-CdA and mitoxantrone in patients with alkylator-failed indolent lymphoma to determine the maximum-tolerated dose (MTD) of this combination and to make preliminary observations about efficacy. PATIENTS AND METHODS Twenty-three patients were treated every 28 to 35 days, in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Ennui or not ennui, that is the question...

Annals of oncology : official journal of the European Society for Medical Oncology • 1996
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…